KIOVIG 100 mg/ml solution for infusion
Sponsors
Janssen - Cilag International, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Universitair Medisch Centrum Utrecht, Takeda Development Center Americas Inc.
Conditions
Primary antibody deficiency:
- Unclassified antibody deficiency (unPAD)
- IgA deficiency
- Specific polysaccharide antibody deficiency (SPAD)
- IgG subclass deficiency (IgSD)
- Common variable immunodeficiency (CVID)
- Agammaglobulinemia (X-linked or otherwise)Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapyRelapsed or Refractory Multiple Myelomaanti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis)
Phase 2
Phase 3
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
Active, not recruitingCTIS2023-503467-41-00
Start: 2022-10-12Target: 310Updated: 2026-01-27
Influencing Progression of Airway Disease in Primary Antibody Deficiency
Not yet recruitingCTIS2024-513124-41-00
Target: 100Updated: 2024-07-12
A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy
Not yet recruitingCTIS2024-518420-80-00
Target: 143Updated: 2026-01-12